Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Because some febrile patients are unable to swallow or retain oral antipyretic drugs, we carried out a double-blind, placebo-controlled trial in which intravenous ibuprofen (IV-ibuprofen) was given to adults hospitalized with fever associated with acute uncomplicated falciparum malaria treated with oral artesunate plus mefloquine. Thirty patients received IV-ibuprofen 400 mg and 30 received placebo every 6 hours for 72 hours. Reduction in the area above 37.0 degrees C versus time curve was significantly greater for IV-ibuprofen than for placebo during the first 72 hours after first administration. No patients developed severe malaria; parasite clearance was delayed in the patients whose fevers were controlled by IV-ibuprofen (median 37.3 hours versus 23.7 hours in the placebo group [P = 0.0024]). This difference did not appear to be clinically important Adverse events, none considered severe, occurred equally in both groups. IV-ibuprofen was effective and well tolerated in reducing fever in febrile inpatients with malaria.

Original publication

DOI

10.4269/ajtmh.2010.09-0621

Type

Journal article

Journal

Am J Trop Med Hyg

Publication Date

07/2010

Volume

83

Pages

51 - 55

Keywords

Acute Disease, Adult, Animals, Antimalarials, Artemisinins, Artesunate, Double-Blind Method, Drug Therapy, Combination, Fever, Humans, Ibuprofen, Injections, Intravenous, Malaria, Falciparum, Mefloquine, Parasitemia, Plasmodium falciparum, Treatment Outcome